Bioprocess Development and Characterization of a 13C-Labeled Hybrid Bispecific Antibody Produced in Escherichia coli
- PMID: 36810521
- PMCID: PMC9944054
- DOI: 10.3390/antib12010016
Bioprocess Development and Characterization of a 13C-Labeled Hybrid Bispecific Antibody Produced in Escherichia coli
Abstract
Monoclonal antibodies (mAbs) are highly efficacious therapeutics; however, due to their large, dynamic nature, structural perturbations and regional modifications are often difficult to study. Moreover, the homodimeric, symmetrical nature of mAbs makes it difficult to elucidate which heavy chain (HC)-light chain (LC) pairs are responsible for any structural changes, stability concerns, and/or site-specific modifications. Isotopic labeling is an attractive means for selectively incorporating atoms with known mass differences to enable identification/monitoring using techniques such as mass spectrometry (MS) and nuclear magnetic resonance (NMR). However, the isotopic incorporation of atoms into proteins is typically incomplete. Here we present a strategy for incorporating 13C-labeling of half antibodies using an Escherichia coli fermentation system. Unlike previous attempts to generate isotopically labeled mAbs, we provide an industry-relevant, high cell density process that yielded >99% 13C-incorporation using 13C-glucose and 13C-celtone. The isotopic incorporation was performed on a half antibody designed with knob-into-hole technology to enable assembly with its native (naturally abundant) counterpart to generate a hybrid bispecific (BsAb) molecule. This work is intended to provide a framework for producing full-length antibodies, of which half are isotopically labeled, in order to study the individual HC-LC pairs.
Keywords: 13C-celtone; 13C-labeled glucose; ambr250 bioreactors; biotherapeutic proteins; knob-into-hole; protein isotopic labeling.
Conflict of interest statement
All authors are employees of Genentech at the time of data collection, and the company provided necessary supports and resources in the study. The objectivity and authenticity of the experimental results and discussion were not affected by the company.
Figures



Similar articles
-
Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation.MAbs. 2022 Jan-Dec;14(1):2111748. doi: 10.1080/19420862.2022.2111748. MAbs. 2022. PMID: 36018829 Free PMC article. Review.
-
Time resolved native ion-mobility mass spectrometry to monitor dynamics of IgG4 Fab arm exchange and "bispecific" monoclonal antibody formation.Anal Chem. 2013 Oct 15;85(20):9785-92. doi: 10.1021/ac402237v. Epub 2013 Sep 26. Anal Chem. 2013. PMID: 24007193
-
Characterization and Monitoring of a Novel Light-heavy-light Chain Mispair in a Therapeutic Bispecific Antibody.J Pharm Sci. 2021 Aug;110(8):2904-2915. doi: 10.1016/j.xphs.2021.04.010. Epub 2021 Apr 21. J Pharm Sci. 2021. PMID: 33894207
-
Platform development for expression and purification of stable isotope labeled monoclonal antibodies in Escherichia coli.MAbs. 2018 Oct;10(7):992-1002. doi: 10.1080/19420862.2018.1496879. Epub 2018 Jul 30. MAbs. 2018. PMID: 30060704 Free PMC article.
-
Engineering therapeutic bispecific antibodies using CrossMab technology.Methods. 2019 Feb 1;154:21-31. doi: 10.1016/j.ymeth.2018.11.008. Epub 2018 Nov 16. Methods. 2019. PMID: 30453028 Review.
Cited by
-
A Highly Efficient Workflow for Detecting and Identifying Sequence Variants in Therapeutic Proteins with a High Resolution LC-MS/MS Method.Molecules. 2023 Apr 12;28(8):3392. doi: 10.3390/molecules28083392. Molecules. 2023. PMID: 37110623 Free PMC article.
-
Comprehensive characterization of higher order structure changes in methionine oxidized monoclonal antibodies via NMR chemometric analysis and biophysical approaches.MAbs. 2024 Jan-Dec;16(1):2292688. doi: 10.1080/19420862.2023.2292688. Epub 2023 Dec 20. MAbs. 2024. PMID: 38117548 Free PMC article.
References
LinkOut - more resources
Full Text Sources